GlassScriptPhysician profile
Elizabeth Chase
NPI 1487374682
$1,022.07
in general payments reported to CMS, 2019-2025
20 companies · $684 in 2025
The $684 reported for 2025 was more than what 79% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $102 · 2024: $236 · 2025: $684.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,022.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,022.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $214.97 | 2024-2025 | Orgovyx, Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $92.99 | 2023-2025 | |
| Procept Biorobotics Corporation | $78.62 | 2024-2025 | Aquabeam System |
| C. R. Bard, INC. & Subsidiaries | $77.24 | 2024-2025 | Bard Urinary Drainage Bag |
| Antares Pharma, INC. | $72.22 | 2025 | Xyosted |
| Janssen Biotech, INC. | $69.30 | 2025 | Rybrevant, Carvykti |
| Tolmar, INC. | $61.01 | 2024-2025 | Eligard |
| Lilly USA, LLC | $46.57 | 2023-2024 | Mounjaro |
| Olympus America INC. | $45.34 | 2025 | Itind System |
| Ferring Pharmaceuticals INC. | $38.40 | 2025 | Adstiladrin |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.08 | 2023-2024 | Jardiance |
| Boston Scientific Corporation | $30.92 | 2025 | Axonics |
| Depuy Synthes Sales INC. | $28.57 | 2024 | Na, Hammerlock |
| Becton, Dickinson and Company | $27.10 | 2025 | Bard Urinary Drainage Bag |
| Coloplast Corp | $25.71 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $17.79 | 2025 | Interstim |
| Abbvie INC. | $17.61 | 2023 | |
| Myriad Genetic Laboratories, INC. | $16.82 | 2025 | Myrisk |
| Urogen Pharma, INC. | $15.35 | 2025 | |
| Endo USA, INC. | $14.46 | 2025 | Xiaflex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Chase listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.